Encephalopathy responsive to thiamine in severe COVID-19 patients

Página do item simplificado
dc.contributor.authorOliveira, Marcus Vinicius Branco de
dc.contributor.authorIrikura, Sergio
dc.contributor.authorLourenço, Fabiani Honorato de Barros
dc.contributor.authorShinsato, Monica
dc.contributor.authorIrikura, Tereza Cristina Duarte Batista
dc.contributor.authorIrikura, Rodrigo Batista
dc.contributor.authorAlbuquerque, Tales Vieira Cavalvanti
dc.contributor.authorShinsato, Vilma Neri
dc.contributor.authorOrsatti, Vinicius Nakad
dc.contributor.authorFontanelli, Antônio Mendes
dc.contributor.authorSamegima, Danyelle Amélia Grecco
dc.contributor.authorGonçalves, Marcus Vinícius Magno
dc.contributor.authorBernabé, Daniel Galera [UNESP]
dc.contributor.institutionUnimed Hospital of Araçatuba
dc.contributor.institutionUniversity of the Region of Joinville (UNIVILLE)
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.date.accessioned2023-03-01T20:33:48Z
dc.date.available2023-03-01T20:33:48Z
dc.date.issued2021-07-01
dc.description.abstractEncephalopathy is one of the most frequent neurological complications of severe Coronavirus Disease 2019 (COVID-19) patients. Cytokine storm and sepsis, hypercatabolic states, the use of furosemide and dialytic therapy represent risk factors for thiamine deficiency and are also found in patients with severe COVID-19. In this retrospective case series, we report clinical and neurological findings of fifteen patients with COVID-19-associated Wernicke Encephalopathy (WE) and their response to treatment with intravenous thiamine. All patients had encephalopathy, with 67% displaying at least one additional sign of classic WE triad (ophthalmoparesis and ataxia). Two patients (13%) had the classic triad. All COVID-19 patients had significant improvement of the neurological manifestations between two to five days after intravenous thiamine administration. Eleven patients (73%) had good neurological outcome at hospital discharge and only two patients (13%) died. This case series suggests that thiamine deficiency may be an etiology of encephalopathy in severe COVID-19 patients and its treatment may represent a safety and low-cost response to reduce the neurological burden.en
dc.description.affiliationUnimed Hospital of Araçatuba
dc.description.affiliationUniversity of the Region of Joinville (UNIVILLE)
dc.description.affiliationLaboratory of Psychoneuroimmunology Psychosomatic Research Center Oral Oncology Center Araçatuba Dental School São Paulo State University – UNESP
dc.description.affiliationUnespLaboratory of Psychoneuroimmunology Psychosomatic Research Center Oral Oncology Center Araçatuba Dental School São Paulo State University – UNESP
dc.identifierhttp://dx.doi.org/10.1016/j.bbih.2021.100252
dc.identifier.citationBrain, Behavior, and Immunity - Health, v. 14.
dc.identifier.doi10.1016/j.bbih.2021.100252
dc.identifier.issn2666-3546
dc.identifier.scopus2-s2.0-85113330829
dc.identifier.urihttp://hdl.handle.net/11449/240813
dc.language.isoeng
dc.relation.ispartofBrain, Behavior, and Immunity - Health
dc.sourceScopus
dc.subjectAcute respiratory distress syndrome (ARDS)
dc.subjectCOVID-19
dc.subjectDelirium
dc.subjectEncephalopathy
dc.subjectThiamine
dc.subjectWernicke encephalopathy
dc.titleEncephalopathy responsive to thiamine in severe COVID-19 patientsen
dc.typeArtigo

Arquivos

Coleções

Araçatuba - COB - Centro de Oncologia Bucal